Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma.

Area of Science:

• Oncology
• Molecular Diagnostics
• Clinical Trial Design

Background:

• Circulating tumor DNA (ctDNA) dynamics during treatment show potential for real-time response assessment and recurrence risk prediction.
• Translating ctDNA insights into actionable clinical decisions remains a challenge.

Purpose of the Study:

• To evaluate a risk-adaptive treatment (RAT) strategy guided by on-treatment ctDNA dynamics in nasopharyngeal carcinoma.
• To determine if this ctDNA-driven approach can improve survival outcomes compared to standard care.

Main Methods:

• A multi-center, non-randomized phase II study (EP-STAR) enrolled patients with nasopharyngeal carcinoma.
• Patients received standard neoadjuvant chemotherapy followed by RAT or standard chemoradiotherapy based on ctDNA clearance trajectory.
• A contemporaneous external cohort that did not receive RAT served as a comparator.

Main Results:

• The 3-year failure-free survival (FFS) in the RAT group was 89.1%.
• Patients receiving RAT demonstrated significantly improved FFS compared to the no-RAT external cohort (HR=0.41, P=0.004).
• The RAT strategy was well-tolerated with no treatment-related deaths.

Conclusions:

• A ctDNA-driven risk-adaptive treatment paradigm shows promise for improving survival in nasopharyngeal carcinoma.
• This approach challenges conventional fixed-course treatment strategies.
• ctDNA dynamics can guide adaptive treatment decisions for better patient outcomes.